We read with interest the report of strongyloidiasis pre and post autologous stem cell transplantation (SCT), reported by Orlent et al. 1 We have studied strongyloidiasis in patients with hematological diseases, and some of these patients underwent autologous SCT. In a prospective study, 22 out of 163 consecutive patients with hematological malignancies had a diagnosis of strongyloidiasis made by the Baermann-Moraes method. 2 Three patients subsequently underwent an autologous SCT. In addition, two other patients developed strongyloidiasis during the pre-engraftment period. None of these five patients had eosinophilia at the time of SCT, confirming the comment of Orlent et al that eosinophilia seems to be unusual in these patients, and is therefore a bad screening method. 1 Most patients from our cohort were symptomatic (81%). 2 However, most symptoms of strongyloidiasis may also be attributed to the underlying malignancy and/or its treatment, making these symptoms poor discriminators between patients with or without strongyloidiasis. Therefore, the development of a good screening method in this population of patients is critical. One screening method would be periodic stool examinations. However, the number of stool samples strongly influences the performance of this method. In our prospective study in hematological patients, the positivity of stool examinations raised from 55% with one sample to 82% with three stool samples. 3 Alternatively, a serologic test could be used. In our study, an ELISA test had sensitivity, specificity, positive and negative predictive values of 68, 89, 48 and 95%, respectively. 3 Another possibility would be to give prophylaxis to all patients from endemic areas. We tested this strategy in a double-blind randomized study comparing thiabendazole and placebo given once every month, and did not find a benefit of giving thiabendazole, with similar incidences of strongyloidiasis and fewer side effects in the placebo group. 4 Despite all these limitations of screening and the high incidence of strongyloidiasis in many parts of the world, disseminated strongyloidiasis and hyperinfection syndrome seem to be unusual, even in endemic areas. 5 None of our patients enrolled in the prospective study, including those who subsequently underwent autologous SCT and the two patients with strongyloidiasis diagnosed during the neutropenic phase of SCT developed a syndrome of hyperinfection or disseminated strongyloidiasis. 3, 4 After having completed these studies, we concluded that, given the low incidence of complications and the endemic character of strongyloidiasis in Brazil, no routine screening or prophylaxis would be performed. Patients who develop complications during transplant that may be attributed to a complication of strongyloidiasis are screened with multiple stool examinations and pre-emptively treated. We have performed more than 250 SCTs in our institution and did not observe any case of disseminated or hyperinfection syndrome. 
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